iBio Inc. (NASDAQ:IBIO) is trading up 11.51% to $1.55 during Thursday’s pre-market session.
View the current price of IBIO shares here.
IBIO closed Wednesday’s regular session at $1.39, up 25.23%, according to Benzinga Pro facts.
Company announces conference presentations
The San Diego-based biotech announced Tuesday that its executives will present data on its obesity treatment candidate, IBIO-610, at two industry conferences in November.
Dr. Cory Schwartzdirector of Research and Early Development at iBio, will present in Atlanta on November 4 at 2:00 PM EST.
His presentation, titled “Discovery and Testing of a First-in-Class Activin E Antagonist Antibody for the Treatment of Obesity,” will include data from non-human primate studies.
See also: What’s causing Meat’s 11% after-hours drop?
PEGS Europe presentation
Martin BrennerCEO and Chief Scientific Officer of the AI-driven biotech, will give a presentation on “A first-in-class anti-activin E antibody induces fat-selective weight loss in diet-induced obese mice” on November 12 at 11:45 AM WET in Lisbon.
“These findings add to a growing body of research that inhibiting Activin E signaling could produce fat-selective weight loss, support long-term weight maintenance, and enhance the benefits of GLP-1 therapies,” Brenner said in the announcement.
Stock performance
The stock is down 43.27% this year, but is up 82.89% over the past six months.
iBio Inc. has a 52-week range of $0.56 to $6.89, with a market cap of $28.15 million and an average daily trading volume of 2.64 million shares.
Benzinga’s Edge Stock Rankings indicate that IBIO is undergoing long-term consolidation. Know how the momentum compares to other household names.
Read next:
Photo courtesy: Shutterstock
Disclaimer: This content was produced in part using AI tools and was reviewed and published by Benzinga’s editorial staff.
#iBio #shares #rise #premarket #trading #iBio #NASDAQIBIO